Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-07-09Clinical Trial Update: A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 2]
Phase 2 study results for tiragolumab in combination with atezolizumab in chemotherapy-naïve patients with locally advanced or metastatic no…
-
CLINICAL_TRIALS trial_result · 2020-07-09Clinical Trial Update: Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia [Phase 2]
Phase 2 trial update on ALD518 for non-small cell lung cancer-related fatigue and cachexia assessing safety, efficacy, and pharmacokinetics.
-
CLINICAL_TRIALS trial_result · 2020-07-09Clinical Trial Update: A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) [Phase 1]
Phase 1 clinical trial assessing necitumumab in combination with abemaciclib in non-small cell lung cancer has completed with results posted…
-
CLINICAL_TRIALS trial_result · 2020-07-09Clinical Trial Update: CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). [Phase 2]
A Phase 2 clinical trial update for CM082 and JS001 in patients with advanced non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2020-07-08Clinical Trial Update: Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating erlotinib hydrochloride given before surgery in stage III non-small cell lung cancer; study terminated with results…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-07-08Clinical Trial Update: A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets [Phase 1, Phase 2]
Clinical trial update for TQ-A3334 tablets evaluating tolerance, pharmacokinetics, and efficacy in phase 1 and phase 2 for non-small cell lu…
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. [Phase 2]
Phase 2 clinical trial update for JS001 in combination therapy for non-small cell lung cancer after first-line chemotherapy.
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) [Phase 1]
Phase 1 trial evaluating CS-7017 in combination with carboplatin/paclitaxel in stage IIIb/IV non-small cell lung cancer has completed with r…
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation [Phase 2]
Phase 2 trial update investigating adjuvant afatinib in stage I-III non-small cell lung cancer with EGFR mutation.
-
CLINICAL_TRIALS trial_result · 2020-07-02Clinical Trial Update: Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC [Phase 2]
Phase 2 trial comparing almonertinib to erlotinib or chemotherapy as neoadjuvant treatment for Stage IIIA-N2 EGFR-mutated non-small cell lun…
-
CLINICAL_TRIALS trial_result · 2020-07-02Clinical Trial Update: A Rollover Protocol of Dacomitinib For Patients In Japan [Phase 2]
Phase 2 rollover protocol trial of dacomitinib in Japanese patients with non-small cell lung cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-07-01Clinical Trial Update: Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer [Phase 2]
Phase 2 trial comparing enzastaurin versus placebo with pemetrexed in advanced or metastatic non-small cell lung cancer has completed with r…
-
CLINICAL_TRIALS trial_result · 2020-07-01Clinical Trial Update: Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation [Phase 2]
Phase 2 trial updating alternating icotinib and chemotherapy for advanced non-small cell lung cancer with EGFR mutation.
-
CLINICAL_TRIALS trial_result · 2020-07-01Clinical Trial Update: Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. [Phase 2]
Phase 2 trial evaluating combination chemotherapy with or without anlotinib for maintenance therapy in non-squamous non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2020-06-23Clinical Trial Update: Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer [Phase 2]
A Phase 2 trial assessing whether adding metformin hydrochloride to chemotherapy and radiation improves outcomes for Stage III non-small cel…
-
CLINICAL_TRIALS trial_result · 2020-06-23Clinical Trial Update: Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy [Phase 3]
Phase 3 clinical trial evaluating pemetrexed in advanced non-small-cell lung cancer comparing progression at progression versus maintenance …
-
CLINICAL_TRIALS trial_result · 2020-06-23Clinical Trial Update: Pulmonary Rehabilitation Before Lung Cancer Resection [Phase 3]
A Phase 3 trial evaluating pulmonary rehabilitation before lung cancer resection in patients with non-small cell lung cancer (and COPD) has …
-
CLINICAL_TRIALS trial_result · 2020-06-23Clinical Trial Update: A Feasibility Study of Chinese Herbs to Manage Cancer-related Symptoms in Patients With Advanced NSCLC [NA]
A completed feasibility study evaluating Chinese herbs to manage cancer-related symptoms in patients with advanced non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2020-06-22Clinical Trial Update: A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks [Phase 3]
Phase 3 trial comparing nivolumab dosing regimens (240 mg every 2 weeks vs 480 mg every 4 weeks) in advanced/metastatic non-small cell lung …
-
CLINICAL_TRIALS trial_result · 2020-06-18Clinical Trial Update: ATOM_local Ablative Therapy [Phase 2]
Phase 2 trial update for atom local ablative therapy in non-small cell lung cancer with activating EGFR mutation.
-
CLINICAL_TRIALS trial_result · 2020-06-16Clinical Trial Update: Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating erlotinib with or without investigational drug CS-7017 in advanced non-small cell lung cancer has completed with re…
-
CLINICAL_TRIALS trial_result · 2020-06-12Clinical Trial Update: Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC [Phase 2]
Phase 2 trial evaluating bevacizumab in combination with gefitinib for advanced non-small cell lung cancer (NSCLC) with progression-free sur…
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study [Phase 3]
A Phase 3 extension study in Japan for the KEYNOTE-189 regimen evaluating pembrolizumab added to pemetrexed and platinum chemotherapy as fir…
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating osimertinib with bevacizumab for leptomeningeal metastasis in EGFR-mutant non-small cell lung cancer is in progress…
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients [Phase 2]
Phase 2 trial investigating CTA expression/methylation and response to pembrolizumab in non-small cell lung cancer.